Dr. Jedd Wolchok is the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in clinical investigation, chief of the immune-oncology service, and director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center. He is additionally the associate director of the Ludwig Center for Cancer Immunotherapy. Dr. Wolchok is one of the two study chairs of the clinical trial “A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab” (NCT01975831).
This study examines combinations of two checkpoint immunotherapies, in patients diagnosed with breast cancer, cervical cancer, colorectal cancer, kidney cancer, and ovarian cancer. One checkpoint inhibitor, durvalumab (Imfinzi™), blocks the PD-L1 pathway, whereas the other, tremelimumab, blocks the CTLA-4 pathway.
Additional investigators working on this trial include:
- Antoni Ribas, M.D., Ph.D., University of California, Los Angeles
- Kunle Odunsi, M.D., UChicago Medicine Comprehensive Cancer Center
- Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center (Other study chair)
- Mario Sznol, M.D., Yale University
- Patrick Dillon M.D., University Virginia Health
- Patrick Ott, M.D., Dana Farber Cancer Institute
- Reva Schneider, M.D., Mary Crowley Cancer Center
Projects and Grants
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (NCT01975831)
Memorial Sloan Kettering Cancer Center | Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Ovarian Cancer | 2013
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001) (NCT01239134)
Memorial Sloan Kettering Cancer Center | Melanoma | 2010
Let's spread the word about Immunotherapy! Click to share this page with your community.